Analgesics
Antiandrogens
Antihistamines
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Metformin Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta Thermotherapy Meta
Melatonin Meta

All Studies   Meta Analysis       

Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit

Bessière et al., JAMA Cardiol., May 1, 2020, doi:10.1001/jamacardio.2020.1787
May 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020, now with p < 0.00000000001 from 423 studies, used in 59 countries.
No treatment is 100% effective. Protocols combine treatments.
5,500+ studies for 119 treatments. c19hcq.org
Study of 40 very serious condition ICU patients, 75% required invasive mechanical ventilation, 63% received vasoactive drugs, 50% received other treatments favoring QT prolongation. HCQ with or w/o AZ was given to 45% and 55% respectively. They showed an increase in QTc, more significant with the combination of HCQ+AZ where prolonged QTc was observed in 36% (10 with ΔQTc >60 milliseconds and 7 with QTc ≥500 milliseconds). No ventricular arrhythmia, including torsades de pointes, was recorded. While these results may not be generalizable outside the ICU, caution is recommended in use, especially with the combination.
Appropriate use and careful analysis of contraindications, risks, and benefits are important. More recent and much larger studies have not shown significant safety concerns, including outpatient RCTs showing no serious adverse events, and even the RECOVERY trial which used an unusually high dose of HCQ (including 237 patients also receiving AZ) reports they "did not show any excess in ventricular tachycardia (including torsade de pointes) or ventricular fibrillation in the hydroxychloroquine arm", and "serious cardiovascular toxicity has been reported very rarely despite the high prevalence of cardiovascular disease in hospitalized patients, the common occurrence of myocarditis in COVID-19, and the extensive use of hydroxychloroquine and azithromycin together."
Bessière et al., 1 May 2020, peer-reviewed, 7 authors.
This PaperHCQAll
Initial Experience Prescribing Commercial Tafamidis, the Most Expensive Cardiac Medication in History
MD, MS Ahmad Masri, PharmD Hongya Chen, MD Catherine Wong, MSN, RN Katherine L Fischer, MD Chafic Karam, MD, MPH Walid F Gellad, MD Stephen B Heitner
JAMA Cardiology, doi:10.1001/jamacardio.2020.1738
program, a specialty pharmacy, and a dedicated pharmacist who spent an average of 1 hour per patient to ensure they can afford tafamidis. As such, our experience might not be easily applicable to other health care settings.
DOI record: { "DOI": "10.1001/jamacardio.2020.1787", "ISSN": [ "2380-6583" ], "URL": "http://dx.doi.org/10.1001/jamacardio.2020.1787", "author": [ { "affiliation": [ { "name": "Hospices Civils de Lyon, Hôpital Cardiologique Louis Pradel, Service d’électrophysiologie et de Stimulation Cardiaque, Université de Lyon, Lyon, France" }, { "name": "Hospices Civils de Lyon, Hôpital Cardiologique Louis Pradel, Centre de Référence National des Troubles du Rythme Cardiaque d’origine Héréditaire, Lyon, France" } ], "family": "Bessière", "given": "Francis", "sequence": "first" }, { "affiliation": [ { "name": "Hospices Civils de Lyon, Hôpital Edouard Herriot, Médecine Intensive - Réanimation, Lyon, France" } ], "family": "Roccia", "given": "Hugo", "sequence": "additional" }, { "affiliation": [ { "name": "Hospices Civils de Lyon, Hôpital Cardiologique Louis Pradel, Service d’électrophysiologie et de Stimulation Cardiaque, Université de Lyon, Lyon, France" }, { "name": "Hospices Civils de Lyon, Hôpital Cardiologique Louis Pradel, Centre de Référence National des Troubles du Rythme Cardiaque d’origine Héréditaire, Lyon, France" } ], "family": "Delinière", "given": "Antoine", "sequence": "additional" }, { "affiliation": [ { "name": "Centre Hospitalier de Valence, Service de Maladies Infectieuses, Valence, France" } ], "family": "Charrière", "given": "Rome", "sequence": "additional" }, { "affiliation": [ { "name": "Hospices Civils de Lyon, Hôpital Cardiologique Louis Pradel, Service d’électrophysiologie et de Stimulation Cardiaque, Université de Lyon, Lyon, France" }, { "name": "Hospices Civils de Lyon, Hôpital Cardiologique Louis Pradel, Centre de Référence National des Troubles du Rythme Cardiaque d’origine Héréditaire, Lyon, France" } ], "family": "Chevalier", "given": "Philippe", "sequence": "additional" }, { "affiliation": [ { "name": "Hospices Civils de Lyon, Hôpital Edouard Herriot, Médecine Intensive - Réanimation, Lyon, France" } ], "family": "Argaud", "given": "Laurent", "sequence": "additional" }, { "affiliation": [ { "name": "Hospices Civils de Lyon, Hôpital Cardiologique Louis Pradel, Centre de Référence National des Troubles du Rythme Cardiaque d’origine Héréditaire, Lyon, France" } ], "family": "Cour", "given": "Martin", "sequence": "additional" } ], "container-title": "JAMA Cardiology", "container-title-short": "JAMA Cardiol", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2020, 5, 1 ] ], "date-time": "2020-05-01T15:01:52Z", "timestamp": 1588345312000 }, "deposited": { "date-parts": [ [ 2020, 9, 16 ] ], "date-time": "2020-09-16T18:36:43Z", "timestamp": 1600281403000 }, "indexed": { "date-parts": [ [ 2024, 5, 13 ] ], "date-time": "2024-05-13T05:19:28Z", "timestamp": 1715577568192 }, "is-referenced-by-count": 189, "issue": "9", "issued": { "date-parts": [ [ 2020, 9, 1 ] ] }, "journal-issue": { "issue": "9", "published-print": { "date-parts": [ [ 2020, 9, 1 ] ] } }, "language": "en", "link": [ { "URL": "https://jamanetwork.com/journals/jamacardiology/articlepdf/2765633/jamacardiology_bessire_2020_ld_200006_1599683720.53957.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "10", "original-title": [], "page": "1067", "prefix": "10.1001", "published": { "date-parts": [ [ 2020, 9, 1 ] ] }, "published-print": { "date-parts": [ [ 2020, 9, 1 ] ] }, "publisher": "American Medical Association (AMA)", "reference": [ { "article-title": "Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72?314 cases from the Chinese Center for Disease Control and Prevention.", "author": "Wu", "journal-title": "JAMA", "key": "hld200006r1" }, { "DOI": "10.1126/science.367.6485.1412", "article-title": "Race to find COVID-19 treatments accelerates.", "author": "Kupferschmidt", "doi-asserted-by": "publisher", "first-page": "1412", "issue": "6485", "journal-title": "Science", "key": "hld200006r2", "volume": "367", "year": "2020" }, { "DOI": "10.1136/bmj.m1166", "article-title": "Covid-19: six million doses of hydroxychloroquine donated to US despite lack of evidence.", "author": "Mahase", "doi-asserted-by": "publisher", "first-page": "m1166", "journal-title": "BMJ", "key": "hld200006r3", "volume": "368", "year": "2020" }, { "DOI": "10.1161/CIRCULATIONAHA.109.192704", "article-title": "Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.", "author": "Drew", "doi-asserted-by": "publisher", "first-page": "1047", "issue": "8", "journal-title": "Circulation", "key": "hld200006r4", "volume": "121", "year": "2010" }, { "article-title": "Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know.", "author": "Yazdany", "journal-title": "Ann Intern Med", "key": "hld200006r5" }, { "DOI": "10.2174/1574884713666180223123947", "article-title": "Drug-induced QT interval prolongation in the intensive care unit.", "author": "Etchegoyen", "doi-asserted-by": "publisher", "first-page": "210", "issue": "4", "journal-title": "Curr Clin Pharmacol", "key": "hld200006r6", "volume": "12", "year": "2017" } ], "reference-count": 6, "references-count": 6, "relation": {}, "resource": { "primary": { "URL": "https://jamanetwork.com/journals/jamacardiology/fullarticle/2765633" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit", "type": "journal-article", "volume": "5" }
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit